The goal of MARC SE-Africa is to better define the extent of antimalarial resistance regionally and to expedite the sharing of such evidence with National Malaria Programmes and their implementation partners.
Together, we will develop evidence-based regional detailed action plans that respond to a growing crisis in malaria, one of the greatest infectious challenges facing Africa. Gains achieved in reducing the burden of malaria and advancing its elimination are now threatened by malaria parasites becoming resistant to the main group of drugs used to treat malaria, the artemisinins.
Self-selected National Malaria Programmes will receive technical support for local adaptation and costing of the regional detailed action plans, and tools for dissemination of dynamically-updated malaria treatment guidelines.
Artemisinin-based combination treatments (ACTs) are the backbone of all currently recommended malaria treatments. The potential impact of widespread ACT resistance in Africa has been estimated at 16 million more malaria cases and nearly 80 000 additional malaria deaths annually. Protecting the efficacy of current first-line malaria treatments is now a top public health priority
Introducing MOXIE-BOT: chatbot aiding malaria control debuted at MIM.
MARC-SE Africa launched the highly anticipated MOXIE-BOT in Rwanda
Read more
Mitigating Antimalarial Resistance Consortium in South-East Africa: Kick-Off meeting in Zanzibar
Caption
Africa writers pull together to tackle drug resistant malaria
Caption
A highlight of the 8th Pan-African Malaria Conference: MARC SE-Africa holds a symposium on antimalarial resistance
Caption
